{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:00:44Z","timestamp":1790935244295,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa220","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T12:07:43Z","timestamp":1603627663000},"page":"173-179","source":"Crossref","is-referenced-by-count":26,"title":["Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6639-9753","authenticated-orcid":false,"given":"Susumu","family":"Okano","sequence":"first","affiliation":[{"name":"Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Asakage","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Gifu University Hospital, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Motegi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute Hospital, Koto, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Sayama, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Onoe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ariizumi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"2021020810353104100_ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021020810353104100_ref2","volume-title":"Cancer Information Service","author":"Cancer Registry and Statistics"},{"key":"2021020810353104100_ref3","first-page":"4779","article-title":"Head and neck cancer: a global perspective on epidemiology and prognosis","volume":"18","author":"Sankaranarayanan","year":"1998","journal-title":"Anticancer Res"},{"key":"2021020810353104100_ref4","doi-asserted-by":"crossref","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Gr\u00e9goire","year":"2010","journal-title":"Ann Oncol"},{"key":"2021020810353104100_ref5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021020810353104100_ref6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/jnci\/djh306","article-title":"Randomized phase III trial of Neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up","volume":"96","author":"Zorat","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021020810353104100_ref7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"2021020810353104100_ref8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"2021020810353104100_ref9","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer","volume":"324","author":"Group TDoVALCS","year":"1991","journal-title":"N Engl J Med"},{"key":"2021020810353104100_ref11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jnci\/88.13.890","article-title":"Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial","volume":"88","author":"Lefebvre","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2021020810353104100_ref12","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/annonc\/mds065","article-title":"Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891","volume":"23","author":"Lefebvre","year":"2012","journal-title":"Ann Oncol"},{"key":"2021020810353104100_ref13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"2021020810353104100_ref14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021020810353104100_ref16","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 docetaxel for larynx preservation","volume":"108","author":"Guillaume","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021020810353104100_ref17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021020810353104100_ref19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"key":"2021020810353104100_ref20","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref21","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2017.76.2591","article-title":"Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial","volume":"36","author":"Geoffrois","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref22","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","article-title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial","volume":"28","author":"Ghi","year":"2017","journal-title":"Ann Oncol"},{"key":"2021020810353104100_ref23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000507733","article-title":"Phase III randomized study of induction chemotherapy followed by definitive radiotherapy + cetuximab versus chemoradiotherapy in squamous cell carcinoma of head and neck: the INTERCEPTOR-GONO study (NCT00999700)","volume":"98","author":"Carlo Merlano","year":"2020","journal-title":"Oncology"},{"key":"2021020810353104100_ref24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10147-019-01418-w","article-title":"Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer","volume":"24","author":"Okano","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2021020810353104100_ref25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2010-S3-13","article-title":"TPF sequential therapy: when and for whom?","volume":"15","author":"Budach","year":"2010","journal-title":"Oncologist"},{"key":"2021020810353104100_ref26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Louis Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021020810353104100_ref27","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/cam4.2852","article-title":"A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck","volume":"9","author":"Enokida","year":"2020","journal-title":"Cancer Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/2\/173\/36212765\/hyaa220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/2\/173\/36212765\/hyaa220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:21:50Z","timestamp":1612815710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/2\/173\/6027890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,9]]},"published-print":{"date-parts":[[2021,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa220","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,12,9]]}}}